FDA Panel Approves Needle-Free Epinephrine Nasal Spray for Anaphylaxis
TL;DR
An FDA advisory panel has approved Neffy, an epinephrine nasal spray produced by ARS Pharmaceuticals Inc., for treating severe allergic reactions, including anaphylaxis, as an alternative to an injection with a needle. The spray is recommended for adults and minors weighing at least 30 kilograms. The company's application now goes to the FDA for approval, with action expected in mid-2023. The spray can treat allergic reactions resulting from food, insect bites or stings, drugs, serum, diagnostic testing substances, and other allergens, as well as idiopathic anaphylaxis and exercise-induced anaphylaxis.
Topics:businesshealth#allergic-reactions#anaphylaxis#ars-pharmaceuticals-inc#epinephrine-nasal-spray#fda#health
- FDA advisers clear hurdle for epinephrine nasal spray The Hill
- FDA Panel Backs Needle-Free Epinephrine for Anaphylaxis Medpage Today
- First epinephrine nasal spray clears key FDA hurdle, promising needle-free alternative CBS News
- Why ARS Pharmaceuticals (SPRY) Stock Is Soaring Today - ARS Pharmaceuticals (NASDAQ:SPRY) Benzinga
- Expert Panel Recommends FDA Approve Neffy Epinephrine Spray Allergic Living
Want the full story? Read the original reporting
Read on The Hill